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In Brief
Resistance to fracture requires healthy
bone mass and quality. However, the
cellular mechanisms regulating bone
quality are unclear. Dole et al. show that
osteocyte-intrinsic TGF-b signaling
maintains bone quality through
perilacunar/canalicular remodeling. Thus,
osteocytes mediate perilacunar/
canalicular remodeling and osteoclast-
directed remodeling to cooperatively
maintain bone quality and mass and
prevent fragility.
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Poor bone quality contributes to bone fragility in dia-
betes, aging, and osteogenesis imperfecta. How-
ever, the mechanisms controlling bone quality are
not well understood, contributing to the current
lack of strategies to diagnose or treat bone quality
deficits. Transforming growth factor beta (TGF-b)
signaling is a crucial mechanism known to regulate
the material quality of bone, but its cellular target in
this regulation is unknown. Studies showing that os-
teocytes directly remodel their perilacunar/canalic-
ular matrix led us to hypothesize that TGF-b controls
bone quality through perilacunar/canalicular remod-
eling (PLR). Using inhibitors and mice with an osteo-
cyte-intrinsic defect in TGF-b signaling (TbRIIocy/),
we show that TGF-b regulates PLR in a cell-intrinsic
manner to control bone quality. Altogether, this study
emphasizes that osteocytes are key in executing the
biological control of bone quality through PLR,
thereby highlighting the fundamental role of osteo-
cyte-mediated PLR in bone homeostasis and
fragility.
INTRODUCTION
Bone fragility is determined by bone mass and quality. Bone
quality encompasses parameters including bone geometry,
porosity, trabecular microarchitecture, and bone extracellular
matrix (ECM) material properties (Hernandez and Keaveny,
2006; Seeman, 2008). Historically, the prognosis of fragility frac-
tures has focused on bone mass, but it is now known that
compromised ECM properties play a causal role in bone fragility
in diabetes, aging, and osteogenesis imperfecta (OI) (Delmas
and Seeman, 2004; Fleischli et al., 2006; Grafe et al., 2014;
Lane et al., 2006; Nalla et al., 2004; Ott, 1993; Van Staa et al.,This is an open access article und2003). Despite the clinical importance of this and other aspects
of bone quality, the management of fragility currently focuses
on improving bone mass. Overcoming this clinical gap in diag-
nosing and treating bone quality requires elucidation of mecha-
nisms that orchestrate the biological control of bone quality in
skeletal health and disease.
Currently, the transforming growth factor beta (TGF-b)
pathway is one of the few signaling pathways known to regulate
bone mass and quality (Alliston, 2014; Balooch et al., 2005;
Mohammad et al., 2009; Chang et al., 2010; Edwards et al.,
2010). In bone, TGF-b produced by bone-forming osteoblasts
is sequestered in the ECM in an inactive, latent form (Sinha
et al., 1998). When released upon osteoclastic resorption of
the ECM, TGF-b exerts pleiotropic effects on osteoblasts, oste-
oclasts, and their progenitors to coordinate bone remodeling
(Dallas et al., 2008; Tang and Alliston, 2013). Aberration in
TGF-b signaling leads to altered bone mass and poor bone qual-
ity in multiple skeletal diseases, including Camurati Engelman
disease (CED) and OI (Grafe et al., 2014; Kinoshita et al.,
2000). While the pathogenesis of the poor bone quality associ-
ated with these diseases has been attributed to imbalanced
osteoclast and osteoblast activity, not much is known about
the causal role of osteocytes and osteocyte-intrinsic TGF-b
signaling in bone fragility.
In addition to regulating the activity of osteoclasts and oste-
oblasts, osteocytes also engage in perilacunar/canalicular re-
modeling (PLR), during which they directly resorb and deposit
bone matrix surrounding their intricate lacuno-canalicular
network (Qing and Bonewald, 2009). This process was origi-
nally called osteocyte osteolysis when it was observed in
pathologic conditions or PLR in metabolically demanding situ-
ations such as lactation or hibernation (Haller and Zimny,
1977; Qing et al., 2012; Qing and Bonewald, 2009; Teti and Zal-
lone, 2009; Wysolmerski, 2013). It is now clear that PLR is a
homeostatic mechanism that helps to maintain mineral homeo-
stasis and the lacuno-canalicular network. Several studies
demonstrate the essential role in PLR of matrix metalloprotei-
nases (Mmps; namely Mmp2, Mmp13, and Mmp14), cathepsinCell Reports 21, 2585–2596, November 28, 2017 2585
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K (Ctsk), carbonic anhydrase 2, and tartrate-resistant acid
phosphatase (Acp5/TRAP) (Kogawa et al., 2013; Qing et al.,
2012; Qing and Bonewald, 2009; Wysolmerski, 2013). Through
loss-of-function studies in mice, these genes were found to be
essential for an intact lacuno-canalicular network, organization
of collagen, and bone matrix mineralization (Holmbeck et al.,
2005; Inoue et al., 2006; Kogawa et al., 2013; Kulkarni et al.,
2012; Qing and Bonewald, 2009; Tang et al., 2012; Tang
and Alliston, 2013; Wysolmerski, 2013), all of which contribute
to bone quality. Macro-mechanical testing of MMP13-deficient
bones revealed a correlation between the loss of PLR and
bone fragility (Tang et al., 2012). Nonetheless, many questions
remain about the relationship between osteocyte-mediated
PLR and bone quality.
In an effort to elucidate the cellular andmolecular mechanisms
that control bone quality, we tested the hypothesis that TGF-b
acts directly on osteocytes to control PLR and that this mecha-
nism accounts for the TGF-b-dependent control of bone quality.
Several lines of evidence support this model, including the ability
of TGF-b to directly regulate the expression of several Mmps
implicated in PLR (Krstic and Santibanez, 2014; Selvamurugan
et al., 2004). To investigate this possible mechanism, we em-
ployed unique in vivo and in vitro models and pharmacologic
TGF-b antagonists similar to those in human clinical trials for
the treatment of bone fragility in OI. Using this approach, we un-
covered the essential role of osteocyte-intrinsic TGF-b signaling
in the control of PLR and fracture resistance and demonstrate
the importance of PLR in bone fragility.
RESULTS
Pharmacologic Inhibition of TGF-b Signaling
Dysregulates PLR
We previously showed that pharmacologic inhibition of the
TGF-b-receptor I (TbRI) kinase using SD-208 increases trabec-
ular bone mass through stimulating osteoblastic bone formation
and repressing osteoclastic resorption (Mohammad et al., 2009).
However, the effect of SD-208 or other TbRI-inhibitory agents on
osteocytes (OCYs) is unknown. To investigate the role of TGF-b
signaling in osteocytes, the most abundant bone cells in cortical
bone (Franz-Odendaal et al., 2006), we examined histologic and
molecular outcomes of osteocyte-mediated PLR in mice treated
with SD-208. As expected, 6 weeks of TbRI-inhibitor treatment
significantly increased trabecular bone mass (Figure S1). Histo-
logic analysis shows a dense and organized network of osteo-
cyte canaliculi in cortical bone of vehicle-treated mice. However,
TbRI-inhibitor treatment caused severe deterioration of the oste-
ocyte canalicular network with a 50% reduction in canalicular
length (Figures 1A and 1B).
The dysregulated canalicular network in TbRI kinase-inhibitor
(TbRI-I)-treated bone resembles that seen in bones deficient
in enzymes essential for PLR (Holmbeck et al., 2005; Inoue
et al., 2006; Kulkarni et al., 2012; Tang et al., 2012). Therefore,
we evaluated the effect of TbRI inhibition on the expression
of genes encoding PLR enzymes, including Mmp2, Mmp13,
and Mmp14, Ctsk, and Acp5 in cortical bone. TbRI-I treat-
ment coordinately reduced the level of mRNA encoding all
five enzymes, relative to vehicle-treated controls (Figure 1C).2586 Cell Reports 21, 2585–2596, November 28, 2017Expression of the ATPase Atp6v0d, is increased in TbRI-I treated
bone (Figure S2). Moreover, TbRI-I treatment also causes a
decline in osteocytic protein expression of MMP13, MMP14,
and CTSK without impacting their viability (Figures 1D–1F).
This strong, concerted repression of several genes required for
osteocyte-mediated PLR upon TGF-b inhibition indicates the
critical role of TGF-b in controlling osteocyte function.
TGF-b Regulates PLR in a Cell-Intrinsic Manner
While systemic inhibitors of TGFb clearly impact lacuno-
canalicular networks and the expression of genes associated
with PLR, it was unclear whether TGF-b exerts its effects on
osteocytes directly or indirectly. Therefore, we examined the
cell-intrinsic effects of TGF-b on MLO-Y4 osteocyte-like cells
and OCY454 osteocytes, which more faithfully mimic osteo-
cytic gene expression. Within 6 hr of treatment, TGF-b
induced expression of Mmp13, Mmp14, and Ctsk mRNA,
as well as Serpine1, a well-known TGF-b-inducible gene in
MLO-Y4 cells (Figures 2A and 2B) (Graycar et al., 1989).
TGF-b also induced expression of Mmp13 and Ctsk, but
not Mmp14, in OCY454 cells (Figures 2C and 2D). Further
supporting the osteocyte-intrinsic role of TGF-b, TGF-b
induced the expression of the osteocyte marker genes
Sclerostin (Sost) and dentin matrix protein-1 (Dmp1) without
affecting phosphate regulating endopeptidase homolog, X
linked (Phex) (Figure S3).
In addition to expressing PLR enzymes, osteocytes engaged
in PLR acidify their microenvironment. Using the pH-sensitive
dye 5-(and-6)-carboxy SNARF-1, AM, we examined the effect
of TGF-b on MLO-Y4 cell acidification. As shown by others
(Kogawa et al., 2013), recombinant human sclerostin (rhSCL)
induces PLR and lowers the intracellular pH (pHi) of MLO-Y4
cells. TGF-b treatment resulted in a larger acidification than scle-
rostin treatment. In contrast, blocking TGF-b signaling with an
in vitro inhibitor of TbRI (SB-431542) relieved this acidification,
such that pHi was equivalent to untreated cells (Figures 2E
and 2F). Altogether, our findings support the possibility that
TGF-b induces PLR in an osteocyte-intrinsic manner.
Osteocyte-Specific Inhibition of TGF-b Signaling
Impairs PLR
To evaluate the osteocyte-intrinsic role of TGFb signaling in vivo,
TGF-b receptor II (TbRII) was deleted in osteocytes using DMP1-
Cremice, resulting in TbRIIocy/mice. We validated the specific
reduction of TbRII expression in osteocytes (but not in other cell
types) of TbRIIocy/ bone relative to DMP1Cre/; TbRIIfl/fl (wild-
type [WT]) littermate controls (Figures 3A and 3B). Abrogation of
TGF-b signaling in TbRIIocy/ bone was validated by reduced
TbRII and Serpine1 gene expression (Figure 3C). Furthermore,
using primary bone marrow cultures from WT and TbRIIocy/
mice, we verified the osteocyte-specific defect in TGF-b
signaling by confirming that osteogenic gene expression is
normal until after these cells differentiate into osteocytes (Fig-
ures S5A–S5D).
Because the systemic inhibition of TGF-b signaling causes
severe deterioration of the osteocyte canalicular network, and
because TGF-b regulates osteocytic expression of PLR
enzymes, we evaluated the lacuno-canalicular network in
Figure 1. Pharmacologic TbRI Inhibition Impairs Perilacunar/Canalicular Remodeling
(A and B) Silver-nitrate-stained images of femoral cortical bone from mice treated with vehicle or TGF-b receptor I kinase inhibitor (TbRI-I; SD-208) treated mice
show osteocyte lacuno-canalicular network (A) and canalicular length (B). Scale bar, 20 mm (n = 6 mice/group).
(C) qPCR analysis of the PLR genes Mmp2, Mmp13, Mmp14, Ctsk, and Acp5 in bones from vehicle- and TbRI-I-treated animals (n = 8 mice/group).
(D–F) Immunohistochemistry (IHC) of MMP13, MMP14, and CTSK and H&E staining of femoral cortical bone of vehicle- and TbRI-I-treated animals. Arrows in the
image indicate positively stained osteocytes (D). Osteocytes positive for MMP13 (E), MMP14 (E), CTSK (F), and HE (F) staining were quantified and normalized to
total bone area. Scale bar, 50 mm (n = 4 mice/group).
Error bars indicate mean ± SEM; *p < 0.05 compared to vehicle from Student’s t test.TbRIIocy/ cortical bone. Upon osteocytic deletion of TbRII, the
canalicular network was abrogated and visibly blunted. Relative
to WT, the length of canalicular projections in TbRIIocy/ bone
was reduced by 50% and the total lacuno-canalicular area was
reduced by 32% (Figures 3D, 3E, and S4A).
Among the panel of PLR genes, expression ofMmp2,Mmp13,
Mmp14, Ctsk, and Acp5 was downregulated in TbRIIocy/mice(Figures 3F and S4B). In fact, the effect of osteocyte-intrinsic
TbRII ablation on PLR gene expression was even more
profound than that produced by TbRI-inhibitor treatment.
Expression of osteocalcin (Oc), bone sialoprotein (Ibsp), Dmp1,
and Phex, genes that control systemic mineral homeostasis,
was unaffected by the absence of osteocytic TGF-b signaling.
Expression of Sost, which is known to be induced by TGF-bCell Reports 21, 2585–2596, November 28, 2017 2587
Figure 2. TGF-b Promotes Cell-Intrinsic Osteocytic Perilacunar/Canalicular Remodeling
(A and B) qPCR analysis of the PLR genesMmp13,Mmp14, Ctsk (A), and Serpine1 (B) upon TGF-b (5ng/mL) treatment in MLO-Y4 cells (n = 3 replicates/group).
(C and D) qPCR analysis of the PLR genesMmp13, Mmp14, Ctsk (C), and Serpine1(D) upon TGF-b (5ng/mL) treatment in OCY454 cells (n = 3 replicates/group).
(E and F) Intracellular pH (pHi) of MLO-Y4 cells after 3 days of TGF-b (5 ng/mL), TbRI inhibitor SB-431542 (10 mM), or recombinant human sclerostin (rhSCL;
10 ng/mL) treatment. Representative image shows the shift in the emission peak from 580 nm to 640 nm after TGF-b treatment of MLO-Y4 cells (E). Scale bar,
100 mm. TGF-b-induced acidification is blocked by SB-431542 (F) (n = 4 replicates/group).
Error bars indicate mean ± SD of 3 independent experiments. *p < 0.05 different from control mRNA; ap < 0.05 different from control pHi; bp < 0.05 different from
TGFb pHi; cp < 0.05 different from rhSCL pHi. Statistical significance was calculated using a Student’s t test.(Loots et al., 2012; Nguyen et al., 2013), was downregulated in
TbRIIocy/ bones (Figure 3G). Protein expression of MMP13,
MMP14, and CTSK in osteocytes of TbRIIocy/ mice was also
significantly reduced 27%–40% compared to WT mice, without
apparent changes in osteocyte number and viability as deter-
mined by H&E and TUNEL staining (Figures 3H, 3I, S4B, and
S4C). These findings corroborated the observations in the
TbRI-I mouse model and revealed the direct role of osteocytic
TGF-b signaling in the regulation of PLR.
To rigorously evaluate the effect of TbRII deletion on lacunar
size, orientation and shape, we utilized synchrotron radiation
micro-tomography (SRmT), which visualizes and quantifies the
osteocyte lacunae in a 3D space. In spite of the dramatic differ-
ences in the canalicular network seen histologically, osteocyte
lacunar volume, shape, and orientation relative to the long axis
of the bone did not differ significantly between TbRIIocy/ and
WT cortical bone (Figures 3J–3M and S4E–S4H). Also using
SRmT, we detected a 3% reduction (p = 0.06) in peak bone min-
eral concentration in diaphyseal cortical bone of TbRIIocy/
mice compared to WT (Figures 3M and S4H). Therefore, osteo-
cyte-intrinsic TGF-b signaling regulates the expression of en-
zymes required for PLR and is essential for the integrity of the
canalicular network and bone matrix mineralization. This not
only reveals a previously unidentified role of TGF-b in osteocytes2588 Cell Reports 21, 2585–2596, November 28, 2017but also adds TGF-b to the short list of factors shown to
regulate PLR.
Osteocyte-Specific Deletion of TbRII Increases
Trabecular Bone Mass by Inhibiting Bone Resorption
Because alterations in TGF-b signaling often impact bone mass
(Balooch et al., 2005; Mohammad et al., 2009), we analyzed the
impact of ablated osteocyte-specific TGF-b signaling on trabec-
ular and cortical bone mass and geometry. Bones of TbRIIocy/
mice showed no gross abnormalities relative to WTmice. Micro-
computed tomography (mCT) analysis revealed a 35% increase
in trabecular bone mass in 8-week-old TbRIIocy/ mice relative
to WT littermates. This gain in mass was attributed to the corre-
sponding increase in trabecular number (26%) and complemen-
tary decrease in trabecular spacing (25%) (Figures 4A–4D;
Table 1). However, osteocytic deletion of TbRII did not affect
cortical bone thickness or geometry (Figures 4K–4M). Cortical
bone mineralization (Figure 4N) of TbRIIocy/mice was reduced
by 4.8%, consistent with the 3% decrease in peak bone mineral
concentration detected by SRmT (Figure 3M). Therefore, osteo-
cyte-intrinsic TGF-b regulates the mass and geometry of trabec-
ular, but not cortical, bone.
To understand the cellular mechanism underlying the
elevated trabecular bone phenotype of TbRIIocy/ mice,
(legend on next page)
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histomorphometry was performed. Neither static nor dynamic
histomorphometric analyses revealed significant differences in
osteoblast or bone formation parameters in TbRIIocy/ bone
(Figures 4E–4G; Table 1). On the other hand, measures of bone
resorption implicate osteocyte-intrinsic TGF-b in the control of
osteoclast function. Specifically, TRAP-positive osteoclasts
were reduced by 40%, along with a 34% reduction in osteoclast
surface in TbRIIocy/mice (Figures 4H and 4I; Table 1). Further-
more, TbRIIocy/ mice showed a substantial reduction in the
ratio of RANKL/OPG mRNA expression due to low levels of the
osteoclastogenic factor RANKL (Rankl) but unaffected levels of
OPG (Opg), a RANKL antagonist (Figures 4J, S5E, and S5F).
Together, these results attribute the high trabecular bone mass
phenotype of TbRIIocy/mice to decreased osteoclast function,
which essentially results from decreased production of RANKL
by TbRII-deficient osteocytes.
Osteocyte Deletion of TbRII Reduces Fracture
Resistance of Bone
Given that TbRIIocy/ cortical bone mass and thickness are
normal, evidence of bone fragility in these mice would be
consistent with defects in bone quality. Despite our prior impli-
cation of TGF-b in bone quality regulation (Balooch et al., 2005;
Chang et al., 2010; Mohammad et al., 2009), the cellular target
responsible for the control of bone quality has since been
elusive. The disruption of PLR and cortical bone mineralization
in TbRIIocy/ bone led us to hypothesize that TGF-b controls
bone quality through regulation of osteocytic PLR. To test
this hypothesis, we performed a series of tests to evaluate
the macromechanical and material behavior of TbRIIocy/
bone.
Macromechanical testing showed reduced fracture resistance
of TbRIIocy/ cortical bone. Using flexural testing, we found that
TbRIIocy/ femora exhibited a 26% decline in the bending
modulus relative to WT bone, indicating a reduced capacity to
resist elastic deformation (Figure 5A). Similarly, the yield stress
was reduced by 27% in TbRIIocy/ bones (Figure 5B). Using
nanoindentation to examine the material properties of the
TbRIIocy/ bone, we found that the Young’smodulus was signif-
icantly lower in TbRIIocy/ bone matrix than in WT bone matrix
(Figure 5C), a finding that is consistent with the reduced
TbRIIocy/ cortical bone mineralization (Figure 4N). The most
dramatic effects were observed in fracture toughness testing,
in which notched TbRIIocy/ cortical bone exhibited a 65%
decrease in total work of fracture compared to WT boneFigure 3. Osteocytic Deletion of TbRII Dysregulates Perilacunar/Cana
(A and B) TbRII-stained osteocytes (A) (arrow, scale bar, 50 mm) in the femoral cort
percentage of positively stained osteocytes normalized to total bone area (B) (n
(C) qPCR analysis of TbRII and Serpine1 in WT and TbRIIocy/ femoral bones. (n
(D and E) Silver-nitrate-stained images of WT and TbRIIocy/ femoral cortical bo
(E) (scale bar, 20 mm; n = 5 mice/group).
(F and G) qPCR analysis of the PLR genes Mmp2, Mmp13, Mmp14, Ctsk, and Ac
TbRIIocy/ bones (n = 8–10 mice/group).
(H and I) Immunohistochemistry (IHC) of MMP13, MMP14, and CTSK and H&E sta
positively stained osteocytes (H) that were quantified and normalized to total bo
(J–M) SRmT shows volume (J), degree of anisotropy (K), orientation (L), and mine
group).
Error bars indicate mean ± SEM; *p < 0.05 compared to WT from Student’s t tes
2590 Cell Reports 21, 2585–2596, November 28, 2017(Figure 5D). These findings are particularly remarkable given
that the severe fragility of TbRIIocy/ bone could not be attrib-
uted to differences in cortical bone mass or geometry.
Accordingly, we sought to learn more about the material
mechanisms responsible for TbRIIocy/ bone fragility. For
example, resistance to crack initiation is primarily imparted
through intrinsic toughening mechanisms, representing a
material’s inherent resistance to microstructural damage. On
the other hand, crack growth toughness stems from extrinsic
toughening mechanisms, which act to shield the crack from
the applied driving force to limit crack propagation (Launey
and Ritchie, 2009).
To distinguish between the effects of osteocyte TbRII defi-
ciency on crack initiation and crack growth, we conducted frac-
ture toughness testing in a variable pressure scanning electron
microscope to simultaneously visualize and quantify crack
behavior. While crack initiation toughness could not be conclu-
sively differentiated between genotypes, the shallow slope of
the R-curve for TbRIIocy/ bones is indicative of reduced crack
growth toughness and a loss of extrinsic toughening mecha-
nisms (Figure 5E). In situ images of crack growth show evidence
of extrinsic toughening by crack deflection and uncracked
ligament bridging in WT bone (Figure 5E, i–iii). Conversely,
the path of cracks in TbRIIocy/ bone tended to be more
linear and shorter relative to their profile extension in WT bones
(Figures 5F and 5G). Therefore, we conclude that TGF-b regu-
lates bone quality in an osteocyte-intrinsic manner, specifically
through extrinsic toughening mechanisms that limit crack
growth. Identification of osteocytes as crucial cellular targets in
the biological control of bone quality raises new questions about
the role of osteocytes and PLR in human bone fragility.
DISCUSSION
This study advances our understanding of bone homeostasis
and fragility by revealing an osteocyte-intrinsic role for TGF-b
signaling. Here, we implicate TGF-b as a crucial regulator of
PLR and pinpoint osteocytes as the cell type principally respon-
sible for the biological control of bone quality. Using either
pharmacologic TGF-b receptor type I kinase inhibitors or a
genetic model of osteocyte-specific TGF-b receptor ablation,
we demonstrate that suppression of TGF-b signaling causes
a severe deterioration of osteocyte canalicular network and
dysregulates the expression of a host of PLR genes. Loss of
osteocyte-intrinsic TGF-b signaling also reduces bone matrixlicular Remodeling
ical bone fromWT and TbRIIocy/mice (8-week-old males) were quantified as
= 5 mice/group).
= 8–10 mice/ group).
ne shows the osteocyte lacuno-canalicular network (D) and canalicular length
p5 (F) and the osteocyte-specific genes Sost, Dmp1, and Phex (G) in WT and
ining of WT and TbRIIocy/ femoral cortical bone. Arrows in the image indicate
ne area (I) (n = 4 mice/group).
ralization (M) of osteocyte lacunae of WT and TbRIIocy/ bone (n = 3–4 mice/
t.
Figure 4. Osteocytic Deletion of TbRII Increases Trabecular Bone Mass but Does Not Affect Cortical Bone Mass
(A–D) mCT analysis of femur from WT and TbRIIocy/ mice (8-week-old males). Representative mCT reconstructions of trabecular bone (A) from mice and
trabecular bone parameters: trabecular bone volume fraction (BV/TV) (B), trabecular number (Tb.N.) (C), and separation (Tb.Sp.) (D). Scale bar, 100 mm (n = 10–11
mice/group).
(E–I) Histomorphometric analysis of femurs from WT and TbRIIocy/ mice (8-week-old males) measures osteoblast number normalized to bone surface
(N.Ob/BS) (E), bone formation rate (BFR) (F), percent mineralizing bone surface per bone surface (MS/BS) (G), osteoclast number normalized to bone surface
(N.Oc/BS) (H), and osteoclast surface normalized to bone surface (Oc.S/BS) (I) (n = 6–7 mice/group).
(J) qPCR analysis of mRNA harvested from WT and TbRIIocy/ bones shows the Rankl/Opg ratio (n = 8–10 mice/group).
(K–N) Representative mCT reconstructions of femoral cortical bone femur fromWT and TbRIIocy/mice (8-week-old males) (K) and the cortical bone parameters
cortical area fraction (Ct. BA/TA) (L), cortical thickness (Ct. Th) (M), and cortical mineralization (Ct. Min) (N). Scale bar, 100 mm (n = 10–11 mice/group).
Data are presented as mean ± SEM; *p < 0.05 compared to WT from Student’s t test.mineralization. Because TbRIIocy/ cortical bone mass and ge-
ometry are normal, the profound fragility of these bones reveals
that TGF-b controls bone quality through an osteocyte-intrinsic
mechanism that relies on PLR. These findings strongly support
the idea that PLR plays a fundamental role in bone homeostasis,
specifically as the cellular mechanism responsible for the main-
tenance of the lacuno-canalicular network and bone quality.
Our findings revealed TGF-b signaling to be a cell-intrinsic
regulator of PLR. Osteocyte-specific inhibition of TGF-b signaling
decreases the expression of several genes that have been func-
tionally implicated in PLR, including Mmp2, Mmp13, Mmp14,Ctsk, and Acp5. The coordinated regulation of these PLR genes
by TGF-b is consistent with the effects of other PLR-regulatory
pathways. Most of these genes are induced by PLR agonists,
such as sclerostin and PTH, but repressed by PLR antagonists,
such as glucocorticoids (Fowler et al., 2017; Kogawa et al., 2013;
Qing et al., 2012). In each case, including in this study, these
changes in gene expression correspond to alterations in the orga-
nization of the canalicular network. Interestingly, expression of
vacuolar ATPases that function inosteocyte acidificationare upre-
gulated in TbRIIocy/ bone, raising the possibility that a feedback
loop compensates for the low level of proteases mediating PLR.Cell Reports 21, 2585–2596, November 28, 2017 2591
Table 1. Skeletal Phenotyping of 8-Week-Old WT and
TbRIIocy/Mice
Parameters WT TbRIIocy/
mCT
Distal Femur
TBV (BV/TV) (%) 0.192 ± 0.016 0.259 ± 0.028a
Conn D (1/mm3) 377.74 ± 29.29 493.37 ± 71.58
Tb. N (1/mm) 6.275 ± 0.215 7.557 ± 0.542a
Tb. Th (mm) 0.043 ± 0.002 0.043 ± 0.001
Tb. Sp (mm) 0.155 ± 0.006 0.126 ± 0.009a
SMI 1.720 ± 0.184 1.063 ± 0.287b
Tb. Min (mg HA/cm3) 1,020.98 ± 9.31 1,014.23 ± 13.36
Midshaft Femur
Ct. BA/TA (%) 0.437 ± 0.006 0.445 ± 0.008
Ct. Th (mm) 0.188 ± 0.004 0.189 ± 0.003
Ct. SMI 0.442 ± 0.239 1.066 ± 0.339
Ct. Min (mg HA/cm3) 1,279.69 ± 15.30 1,217.59 ± 16.136a
Histomorphometry
Static parameters
OV/BV 0.007 ± 0.001 0.004 ± 0.001
OS 0.14 ± 0.02 0.12 ± 0.04
OS/BS (%) 0.04 ± 0.01 0.03 ± 0.01
O. Wi (mm) 3.28 ± 0.21 2.79 ± 0.36
N.Ob 61.00 ± 5.61 60.94 ± 8.81
N.Ob/BS (/mm) 19.01 ± 2.57 18.24 ± 2.38
Oc.S 0.83 ± 0.07 0.68 ± 0.01c
Oc.S/BS (%) 0.12 ± 0.01 0.08 ± 0.01a
N.Oc 39.57 ± 3.10 30.17 ± 1.66a
N.Oc/BS (/mm) 5.63 ± 0.44 3.40 ± 0.28a
Dynamic Parameters
MS/BS (%) 0.15 ± 0.01 0.16 ± 0.01
MAR (mm/d) 1.84 ± 0.13 1.89 ± 0.17
BFR/BS (mm2. mm3. d) 0.28 ± 0.03 0.30 ± 0.03
mCT and histomorphometry analysis revealed significant differences in
trabecular bone phenotype, cortical mineralization, and osteoclast
behavior between wild-type and TbRIIocy/ mice, but no differences
were observed in cortical bone volume or osteoblast behavior. Bone
parameters measured by mCT include trabecular bone volume fraction
(TBV), connectivity density (Conn D), trabecular number (Tb. N), trabec-
ular thickness (Tb. Th), trabecular separation (Tb. Sp), structural model
index (SMI), trabecular mineralization (Tb. Min), cortical bone volume
fraction (Ct. BV/TV), cortical thickness (Ct. Th), cortical SMI, and cortical
mineralization (Ct. Min), with n = 10–11 mice per group. Histomorphom-
etry parameters measured include osteoid volume (OV/BV), osteoid
surface (OS), osteoid width (O.Wi), osteoblast number (N. Ob), osteoblast
surface (N. Ob/BS), osteoclast surface (Oc.S), eroded bone surface
(Oc.S/BS), osteoclast number (N. Oc), osteoclast number (N.Oc/BS),
mineralization surface (MS/BS), bone formation rate (BFR), and mineral
apposition rate (MAR), with n = 6–7 mice per group. Data are presented
as mean ± SEM.
ap < 0.05 versus WT group, Student’s t test.
bp = 0.06 versus WT group, Student’s t test.
cp = 0.07 versus WT group, Student’s t test.
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the lacuno-canalicular network and on bone matrix differ in
important ways. In addition to alterations in the canalicular
network, lactation and glucocorticoid treatment cause
changes in lacunar size (Fowler et al., 2017; Qing et al.,
2012). Furthermore, collagen organization is disrupted in
MMP13-deficient mice and in mice treated with glucocorti-
coids. In TbRIIocy/ mice, neither collagen organization nor
lacunar volume, shape, and orientation were impacted. In
this study, PLR-mediated changes were observed at osteocyte
canaliculi alone. Interestingly, emerging data from our lab and
others (Fowler et al., 2017; Kaya et al., 2017; Tang et al., 2012)
suggest that remodeling by osteocytes may be spatially
defined, such that some circumstances favor remodeling at
lacunae, whereas others will promote remodeling around
canaliculi. Additional studies will be needed to determine the
extent to which this is true.
The in vitro analysis of osteocyte acidification is a useful surro-
gate of PLR, but additional research is needed to better under-
stand the cell biology of PLR. Nonetheless, TGF-b clearly acts
directly on osteocytes to calibrate the extent of PLR and is
required for the maintenance of the lacuno-canalicular network.
Importantly, it is possible that the degenerated canalicular net-
works in our mouse models of impaired TGF-b signaling result
from defective osteocyte integration into the bone matrix.
A shorter time course or an inducible model would be needed
to conclusively address this question. However, our previous
studies have shown similar canalicular degeneration within
21 days of glucocorticoid treatment (Fowler et al., 2017) or a
week of lactation (unpublished data) (Kaya et al., 2017; Qing
et al., 2012; Qing and Bonewald, 2009; Wysolmerski, 2013),
thereby indicating that changes in the canalicular network can
occur rapidly in a manner that is independent of a maturation
defect.
The critical role of TGF-b in osteocytes complements its ac-
tions in osteoblasts, osteoclasts, and their progenitors, where
it couples bone formation to resorption (Dallas et al., 2008).
Thus, it is not surprising that osteocyte-intrinsic ablation of TbRII
would inhibit osteoclast function due to reduced levels of RANKL
expression by osteocytes. Whether by systemic TbRI inhibition,
expression of a dominant negative TGFb type II receptor in
osteoblasts, or in TbRIIocy/ mice, trabecular bone mass is
increased due to reduced RANKL expression and reduced os-
teoclastogenesis (Edwards et al., 2010; Filvaroff et al., 1999; Mo-
hammad et al., 2009). Though we cannot completely exclude a
causal role of TbRIIocy/ osteocyte canalicular degeneration in
the trabecular bone phenotype, our current and previous data
suggest that TGF-b’s regulation of RANKL expression is cell
intrinsic. On the other hand, the complexity of TGF-b crosstalk
in bone underlies the unique, and at times apparently contradic-
tory, bone phenotypes that result from manipulating TGF-b
signaling in one cell type or another (Dallas et al., 2008; Tang
and Alliston, 2013). Furthermore, in bone and in many other tis-
sues, the effect of TGF-b is nonlinear, such that either increased
or decreased TGF-b signaling can produce an osteoporotic
phenotype (Balooch et al., 2005; Borton et al., 2001; Erlebacher
and Derynck, 1996). Despite this known complexity, we were
surprised by the low mineral concentration of TbRIIocy/ bone,
Figure 5. Osteocytic Deletion of TbRII Re-
duces Bone Material Properties at Multiple
Length Scales
Mechanical testing on femurs from WT and
TbRIIocy-/- (8-week-old males).
(A–B) Flexural tests of intact femurs shows
bending modulus (A) and yield stress (B) (n = 5
mice/group).
(C) Nanoindentation of mid-diaphyseal femoral
bone shows that tissue elastic modulus (n = 3
mice/group).
(D–E) In situ fracture toughness testing of notched
femurs subjected to 3-point bending in a variable
pressure SEM shows total work of fracture (WoF)
(D) (n = 5 mice/group) and WoF R-curves pro-
duced by calculating WoF at each instance of
crack propagation (E) (n = 3 mice/group). Three
stages of crack growth are shown for aWT sample
(i–iii) (scale bar, 100 mm), with pre-existing notch or
crack in black and new crack extension in red, and
the corresponding points are indicated in the
R-curve.
(F–G) The decrease in TbRIIocy-/- bone of the
extrinsic toughening mechanism, crack deflec-
tion, is readily seen in two representative samples
(F) (scale bar, 100 mm) and in quantification of the
ratio of total crack length to crack extension
(G) (n = 5 mice/group).
Data are presented as mean SD. 95% confidence
intervals in (E) are calculated based on a power fit.
*p < 0.05 different from WT group from Student’s
t test.given that mineralization is increased by systemic post-natal
TbRI-I treatment (Edwards et al., 2010; Mohammad et al.,
2009). Given that osteocyte canaliculi are sites of secondary
mineralization, it is possible that the reduced canalicular length
in the TbRIIocy/ bones reduces surface area available for
mineralization. Moreover, the increased expression of vacuolar
ATPase may create an acidic microenvironment that is unfavor-
able for mineralization. Additional studies will be needed to
discern the mechanisms by which pharmacologic disruption of
TGF-b signaling affects bone mineralization differently from
genetic ablation of TbRII specifically in osteocytes.
Bone strength relies on bone mass and bone quality, both of
which depend on the ability of TGF-b to coordinate the function
of osteoblasts, osteoclasts, and osteocytes. In spite of the fact
that bone quality contributes to at least half of fractures in people
with clinically normal bone mass (Schuit et al., 2004; Sornay-Re-
ndu et al., 2007), the cellular mechanisms controlling boneCell Reportsquality have remained unclear. Under-
standing these mechanisms is a critical
step in improving the diagnostics and
therapeutics for fragility fractures (Her-
nandez and Keaveny, 2006; Seeman,
2008). This study represents the most
definitive evidence so far implicating
osteocyte-mediated PLR in the control
of bone quality. Previous studies by our
group and others show that bone qualityis impaired following glucocorticoid treatment or systemic abla-
tion of MMP13 and that PLR is impaired in each case (Fowler
et al., 2017; Lane et al., 2006; Tang et al., 2012). Here, we find
that osteocyte-specific deletion of TGF-b signaling caused de-
fects in PLR, cortical bone mineralization, flexural strength,
ECM material properties, and fracture toughness without im-
pacting cortical bone mass. In diseases like Camurati Engelman
syndrome and OI, both of which are characterized by excessive
TGF-b signaling (Grafe et al., 2014; Kinoshita et al., 2000; Tang
et al., 2009), deregulation of osteocyte-mediated remodeling
may contribute to bone fragility. Similarly, the extent to which
dysregulated PLR contributes to the fragility in other skeletal
diseases, including renal osteodystrophy, secondary hyperpara-
thyroidism, and glucocorticoid-induced osteoporosis, is an
important area of further investigation. If so, PLR could be an
attractive therapeutic target for improving fracture resistance in
many conditions.21, 2585–2596, November 28, 2017 2593
In conclusion, this study emphasizes the need to identify the
cellular and molecular mechanisms regulating bone quality to
develop new therapies to address the significant unmet clinical
need for the treatment of bone fragility. Current therapeutics
can improve 70% of trabecular fractures but only 20%–40% of
cortical bone fractures, which is precisely where PLR dysregula-
tion is most profound (Ahmed et al., 2015; Chen and Sambrook,
2011; Rivadeneira and Ma¨kitie, 2016). A combination of systems
analysis of genome-wide association study (GWAS) data from
clinical cohorts, along with functional in vivo and in vitro studies,
can shed light on new molecular targets to control bone fragility
and expand the pool of genetic markers needed for fracture risk
assessment and prevention.
EXPERIMENTAL PROCEDURES
Mice
To block TGF-b signaling systemically, 5-week-old C57BL/6 male mice of
equal weight were administered either vehicle (1% methylcellulose) or a spe-
cific inhibitor of TGFbRI (SD-208, 60 mg/kg twice daily by oral gavage) for
6 weeks (Mohammad et al., 2009). We also generated mice with osteocyte-
specific ablation of TbRII), which effectively blocks osteocyte sensitivity to
TGF-b ligand. Homozygous TbRII-floxed mice that possess loxP sites flanking
exon 4 of the targeted gene were backcrossed for 3 generations into a
C57BL/6 background and subsequently bred with hemizygous 10kb-
DMP1-Cre+/ mice, which express Cre recombinase primarily in osteocytes
(Leve´en et al., 2002; Lu et al., 2007). Half of the mice from the resulting cross
were DMP1-Cre+/;TbRIIflfl (named TbRIIocy/ mice) and half were DMP1-
Cre/;TbRIIfl/fl littermate controls (WT mice), as confirmed by PCR genotyp-
ing. All animal procedures were approved by the Institutional Animal Care
and Use Committee of the University of California, San Francisco and the
Indiana University School of Medicine.
Morphological Analysis
For skeletal phenotyping, femurs harvested from 8-week-old male mice (n = 8
mice per group) were cleaned of soft tissue and fixed in 10% neutral buffered
formalin for mCT. For mCT, fixed femurs were stored in 70% ethanol. For histo-
morphometry, 7-week-old male mice were administered with two intraperito-
neal injections of calcein (20 mg/kg body weight, Sigma) 10 and 3 days prior to
euthanasia. The harvested femurs were fixed in 10% neutral buffered formalin
for 48 hr, processed, and embedded in a methylmethacrylate resin (MMA)
plastic resin. Additional details of mCT and histomorphometry procedures
are described in Supplemental Experimental Procedures.
qRT-PCR Analysis
We purified RNA from cells in culture and from bones dissected from soft tis-
sues using the miRNeasy mini kit (QIAGEN, Valencia, CA) following the manu-
facturer’s protocol. In vitro results are representative of n = 3 replicates per
group and 3 independent experiments. For bones (humeri from n R 8 mice
per group), proximal and distal regions were cut off and marrow was removed
by centrifugation before RNA extraction. The majority of RNA obtained from
bone using this method is osteocyte derived, with very little contribution
from osteoblasts (Halleux et al., 2012). Additional details of qRT-PCR analysis
are described in Supplemental Experimental Procedures).
Immunohistochemistry
For immunohistochemistry, paraffin-embedded (7 mm thick) sections were
incubated with primary antibodies for anti-MMP13 (1:100; Abcam, ab39012),
anti-MMP14 (1:100; Abcam, ab38971), anti-CTSK (1:75; Abcam, ab19027),
or anti-TbRII (1:500; Abcam, ab186838). This was followed by incubation
with corresponding biotinylated secondary antibody, avidin-conjugated
peroxidase, and diaminobenzidine substrate chromogen system (Innovex Uni-
versal Animal IHC kit). Corresponding nonimmune immunoblobulin Gs (IgGs)
were used as negative controls. H&E and TUNEL-DAPI staining were2594 Cell Reports 21, 2585–2596, November 28, 2017performed to visualize osteocyte number and apoptosis. Ploton silver staining
(Ja´uregui et al., 2016; Ploton et al., 1986) was performed for visualization of the
osteocyte lacuno-canalicular network. Images were acquired using a Nikon
Eclipse E800 bright-field microscope and analyzed with ImageJ. Sections
were evaluated for one femur from each of nR 4 mice per group. Additional
details of immunohistochemistry and image analysis are described in
Supplemental Experimental Procedures.
Cell Culture
TheMLO-Y4 osteocyte-like cell line (generously provided by L. Bonewald) was
maintained in a-MEM supplemented with 2.5% fetal bovine serum, 2.5%
bovine calf serum, and 1% penicillin-streptomycin. The OCY454 osteocyte
cell line (generously provided by P. Divieti-Pajevic) was cultured in a-minimum
essential media (a-MEM) supplemented with 10% fetal bovine serum and 1%
antibiotic/ antimycotic (Gibco). For treatment, cells were cultured in a-MEM
containing 0.5%–1% fetal bovine serum supplemented with 5 ng/mL
TGF-b1 (Humanzyme, HZ-1011), 10 mM SB431542 (Sigma, S4317), or
10 ng/mL rhSCL (R&D Systems) for the indicated times.
pHi Assay
pHi was measured in transfected or untransfected MLO-Y4 cells treated
with TGF-b1, SB431542, or rhSCL using the pH-sensitive fluorescent dye
5-(and-6)-carboxy SNARF-1, AM (Molecular Probes) as described previously
(Kogawa et al., 2013). Briefly, after 3 days of culture in the indicated conditions,
cells were washedwith PBS and loadedwith 5-(and-6)-carboxy-SNARF-1, AM
at 37C for 30minutes, at a final concentration of 10 mMand visualized under a
Leica TCS SPE confocal microscope (n = 4 replicates per group and 3
independent experiments). Additional details of the procedure are provided
in Supplemental Experimental Procedures.
SRmT
SRmT studies were used to assess the degree of mineralization of bone as well
as the volume and degree of anisotropy of osteocyte lacunae. The mid-diaph-
ysis of 8-week-old male mouse femurs were scanned with 20 keV X-ray
energy, with a 300 ms exposure time, using a 53magnifying lens for a spatial
resolution of 1.3 mm (n = 3–4 mice/ group). Additional details of the SRmT
procedure are described in Supplemental Experimental Procedures.
Mechanical Tests
To measure bone quality, we assessed the macromechanical properties and
the bone matrix material properties using flexural strength tests, in situ frac-
ture toughness tests, and nanoindentation. Briefly, from 8-week-old
TbRIIocy/ and WT mice (n = 3–5 mice per group), intact femurs were
isolated, cleaned of soft tissue, and stored in Hanks’ balanced salt solution
(HBSS). Details of the flexural strength tests, in situ fracture toughness
tests, and nanoindentation procedures are described in Supplemental
Experimental Procedures.
Statistical Analysis
All values are expressed asmean ± SEM ormean ± SD as appropriate for each
assay. Group sizes were determined by power calculations providing 80%
probability of detecting a significant difference (p % 0.05). Group size ‘‘n’’ is
denoted in the figure legends. For in vivo data, n refers to the number of
mice analyzed per group. For in vitro data, n refers to the number of indepen-
dent experiments performed. An unpaired two-tailed Student’s t test was used
to compare the means of two groups using GraphPad Prism (GraphPad
Software). Data points falling more than 2 SDs from the mean were excluded.
Variances ranged from 12.5% to 20% and were similar between groups. No
blinding was used during analysis. In all figures, p % 0.05 was considered
statistically significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, and one table and can be found with this article online at https://
doi.org/10.1016/j.celrep.2017.10.115.
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